A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity

Vaccine

Volumn 23, Issue 37, 2005, Pages 4553-4564

  Chakrabarti, Rabindranath ^a   Zhou, Zheng F ^b   Chang, Yigang ^c   Prud'homme, Gérald J ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

B7; Cancer vaccine; Carcinoembryonic antigen (CEA); CTLA 4; DNA vaccination; IL 10; Regulatory T cells; Transforming growth factor beta

Indexed keywords

B7 ANTIGEN; CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; GAMMA INTERFERON; HYBRID PROTEIN; IMMUNOGLOBULIN; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 4; MUTANT PROTEIN; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CELL INTERACTION; CELL TYPE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG EFFICACY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REJECTION;

ANIMALS; ANTIGENS, CD; ANTIGENS, CD28; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION; CANCER VACCINES; DRUG SYNERGISM; IMMUNOCONJUGATES; IMMUNOGLOBULINS; LYMPHOCYTE ACTIVATION; MICE; MICE, MUTANT STRAINS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 22744433685     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.05.002     Document Type: Article

References (41)

1. S. Gurunathan, D.M. Klinman, and R.A. Sedar Vaccines: immunology, applications, and optimization Annu Rev Immunol 17 2000 927 974
2. G. Ada, and I. Ramsaw DNA vaccination Expert Opin Emerg Drugs 8 2003 27 35
3. W.W. Leitner, and J. Thalhamer DNA vaccination for non-infectious disease: new treatments for tumors and allergy Expert Opin Biol Ther 3 2003 627 638
4. K. Haupt, M. Roggendorf, and K. Mann The potential of DNA vaccination against tumor-associated antigens for anti-tumor therapy Exp Biol Med (Maywood) 227 2002 227 237
5. G.J. Prudhomme DNA vaccination against tumors J Gene Med 7 2005 3 17
6. K. Song, Y. Chang, and G.J. Prudhomme Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and non-viral cytokine gene transfer Gene Ther 7 2000 481 492
7. K. Song, Y. Chang, and G.J. Prudhomme IL-12 plasmid-enhanced DNA vaccination against carcinoembryonic antigen (CEA) studied in immune gene knockout mice Gene Ther 7 2000 1527 1535
8. R. Chakrabarti, Y. Chang, and G.J. Prudhomme Plasmid encoding membrane-bound IL-4 and IL-12 strongly co-stimulate DNA vaccination against carcinoembryonic antigen (CEA) Vaccine 22 2004 1199 1205
9. P. Loke, and J.P. Allison Emerging mechanisms of immune regulation: the extended B7 family and regulatory T cells Arthritis Res Ther 6 2004 208 214
10. + T cells Curr Opin Immunol 15 2003 690 696
11. T.J. Paradis, E. Floyed, J. Burkwit, S.H. Cole, B. Brunson, and E. Elliot The anti-tumor activity of anti-CTLA-4 is mediated through its induction of IFN gamma Cancer Immunol Immunother 50 2001 125 133
12. P.D. Gregor, J.D. Wolchok, C.R. Ferron, H. Buchinsky, J. Guevara-Patino, and M.A. Pearls CTLA-4 blocked in combination with xenogenic DNA vaccines enhances T-cell response, tumor immunity and autoimmunity to self antigens in animal and cellular model systems Vaccine 22 2004 1700 1708
13. S.I. Abrams Role of anti-CTLA-4 therapies in the treatment of cancer Curr Opin Mol Ther 6 2004 71 77
14. M. Moro, A.M. Gasparri, S. Pagano, M. Bellone, P. Tornaghi, and F. Veglia Induction of therapeutic T-cell immunity by tumor targeted with soluble recombinant B7-immunoglobulin co-stimulatory molecules Cancer Res 59 1999 2650 2656
15. K. Sturmhoefel, K. Lee, G.S. Grey, J. Thompson, R. Zollner, and M. O'Toole Potent activity of soluble B7-1-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant Cancer Res 59 1999 4964 4972
16. T. Todo, R.I. Martuza, M.I. Dallman, and S.D. Rabkin In situ expression of soluble B7-1 in the context of oncolytic herpes simplex virus induces potent anti-tumor immunity Cancer Res 61 2001 153 161
17. Z.F. Zhou, Y. Peretz, Y. Chang, D.S. Miao, X. Li, and G.J. Prud'homme Intramuscular gene transfer of soluble B7-1/IgG1 fusion cDNA induces potent antitumor immunity as an adjuvant for DNA vaccination Cancer Gene Ther 10 2003 491 499
18. P. Zheng, Y. Wu, Y. Guo, C. Lee, and Y. Liu B7-CTLA4 interactions enhance both production of anti-tumor cytotoxic T lymphocytes and resistance to tumor challenge Proc Natl Acad Sci 95 1998 6284 6289
19. Y. Wu, Y. Guo, Y. Huang, P. Zheng, and Y. Liu CTLA-4-B7 interaction is sufficient to co-stimulate T cell clonal expansion J Exp Med 185 1997 1327 1335
20. J.A. Gross, E. Callas, and J.P. Allison Identification and distribution of costimulatory receptor CD28 in the mouse J Immunol 148 1992 380 388
21. E.W. Woo, H.C. Yeh, C.S. Chu, K. Schlienger, R.G. Carroll, and C.H. Riley Cutting edge: regulatory T cells fro lung cancer patients directly inhibit autologous T cell proliferation J Immunol 168 2002 4272 4276
22. P.A. Taylor, C.J. Lee, S. Fournier, J.P. Allison, A.H. Sharpe, and B.R. Blazar B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via R-T interactions J Immunol 172 2004 34 39
23. high T regulatory cells with target (allo)antigen specificity J Immunol 173 2004 2866 2876
24. S. Paust, L. Lu, N. McCarty, and H. Cantor Engagement of B7 on effector T cells by regulatory T cells prevents autoimmune disease Proc Natl Acad Sci 101 2004 10398 10403
25. C.B. Jago, J. Yates, N.O. Camara, R.J. Lecher, and G. Lombardi Differential expression of CTLA-4 among T cell subsets Clin Exp Immunol 136 2004 463 471
26. + regulatory T cell function Eur J Immunol 34 2004 1 10
27. D.M. Samson, and N.D. Hall B7/BB1, the ligand for Cd28, is expressed on repeatedly activated human T cells in vitro Eur J Immunol 23 1993 295 298
28. M.R. Prabhu Das, S.S. Zamvil, F. Borriello, H.L. Weiner, A.H. Sharpe, and V.K. Kuchroo Reciprocal expression of costimulatory molecules, B7-1 and B7-2, on murine T cells following activation Eur J Immunol 25 1995 207 211
29. M. Azuma, H. Yssel, J.H. Philips, H. Spits, and L. Lanier Functional expression of B7/BB1 on activated T lymphocytes J Exp Med 177 1993 845 850
30. V. Wasilevko, A. Ghochikyan, and N. Sadzikava Immunization with a vaccine that combines the expression of MUC1 and B7 costimulatory molecules prolongs the survival of mice and delays the appearance of mouse mammary tumors Clin Exp Metastasis 20 2003 489 498
31. X. Bai, J. Liu, K.F. May Jr., Y. Guo, P. Zheng, and Y. Liu B7-CTLA4 interaction promotes cognate destruction of tumor cells by cytotoxic T lymphocytes in vivo Blood 99 2002 2880 2889
32. P.E. Fields, R.J. Finch, G.S. Gray, R. Zollner, J.L. Thomas, and K. Sturmhoefel B7.1 is a quantitatively stronger costimulus than B7.2 in the activation of naive CD8+ TCR-transgenic T cells J Immunol 161 1998 5268 5275
33. G.J. Prud'homme, Y. Chang, and X. Li Immunoinhibitory DNA vaccine protects against autoimmune diabetes through cDNA encoding a selective CTLA-4 (CD152) ligand Hum Gene Ther 13 2002 395 406
34. H. Zhou, M. Sequeira, M.E. Goad, J. Erickson, A. Wong, and E. Clark Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with adriamycin and cytoxan chemotherapy Clin Immunol 101 2001 303 314
35. J.C. Schwartz, X. Zhang, S.G. Nathenson, and S.C. Almo Structural mechanisms of costimulation Nat Immunol 3 2002 427 434
36. J.L. Riley, and C.H. June The CD28 family: a T cell rheostat for therapeutic control of T cell activation Blood 105 2005 13 21
37. A.V. Collins, D.W. Brodie, R.J. Gilbert, A. Iaboni, R. Manso-Sancho, and B. Walse The interaction properties of costimulatory molecules revisited Immunity 17 2002 201 210
38. C.A. Chambers, M.S. Kuhns, J.G. Egen, and J.P. Allison CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Annu Rev Immunol 19 2001 565 594
39. L. Chen Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity Nat Rev Immunol 4 2004 336 347
40. A.L. Mellor, P. Chandler, B. Baban, A.M. Hansen, B. Marshall, and J. Pihkala Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase Int Immunol 16 2004 139 1401
41. T. Takahashi, T. Tagami, S. Yamazaki, T. Uede, J. Shimizu, and N. Sakaguchi Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4 J Exp Med 192 2000 303 310